Development status of miltefosine as first oral drug in visceral and cutaneous leishmaniasis

Medical Microbiology and Immunology

Volumn 190, Issue 1-2, 2001, Pages 85-87

  Fischer, C ^a   Voss, A ^b   Engel, J ^a  

^a ASTA MEDICA AG   (Germany)

^b BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CHOLINE DERIVATIVE; MILTEFOSINE;

ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN LEISHMANIASIS; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 0035175731     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004300100087     Document Type: Article

References (12)

1. Overview on the clinical development of miltefosine solution (Miltex) for the treatment of cutaneous breast cancer
2. The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani
3. Practical guide for the treatment of leishmaniasis
4. Leishmaniasis
5. Miltefosine, an oral agent, for the treatment of Indian visceral Leishmaniasis
6. Hexadecylphosphocholine: Oral treatment of visceral Leishmaniasis in mice
7. Ether lipid metabolism, GPI anchor biosynthesis and signal transduction are putative targets for anti-leishmanial alkylphospholipid analogues
8. Treatment of visceral leishmaniasis - Current status
9. Trial of oral miltefosine for visceral Leishmaniasis
10. Oral treatment of visceral Leishmaniasis with miltefosine
11. Short-course oral miltefosine treatment for visceral leishmaniasis
12. Hexadecylphosphocholine, a new ether-lipid analogue. Studies on the antineoplastic activity in vitro and in vivo